Ospedale Santa Maria Annunziata

Running trials

• Not yet recruiting

  DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

  2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source

• Recruiting

  Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance

  NCT07855679· Azienda Ospedaliero-Universitaria Careggi· Source

• Recruiting

  Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

  NCT06994377· European Institute of Oncology· Source

• Recruiting

  Prevention ICONA Dedicated Ensemble

  NCT07186244· Fondazione ICONA· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· Phase 3· University Of Nottingham· Source

• Recruiting

  Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

  NCT04662723· Phase 4· Fondazione Schena· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Iperboreal Pharma Srl· Source

• Active, not recruiting

  Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study)

  2024-518909-18-00· Phase 3· Societa Italiana Di Malattie Infettive E Tropicali SIMIT· Source

• Active, not recruiting

  Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

  NCT04722575· Phase 2· Fondazione Melanoma Onlus· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting
• Coronary artery disease1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

  NCT04810182· Istituto Oncologico Veneto IRCCS· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  NCT04191499· Phase 2/3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• IgA nephropathy5 works · 1 trial